Clinical Trials Logo

Carcinoma in Situ clinical trials

View clinical trials related to Carcinoma in Situ.

Filter by:

NCT ID: NCT03345420 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NOVEMBER
Start date: December 12, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

NCT ID: NCT03317405 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Start date: October 31, 2018
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies the side effects and best dose of endoxifen hydrochloride in treating participants who are undergoing breast surgery. Endoxifen hydrochloride may treat or reduce the risk of breast cancer.

NCT ID: NCT03300557 Active, not recruiting - Clinical trials for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Start date: November 15, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03267680 Active, not recruiting - Clinical trials for Cervical Squamous Cell Carcinoma In Situ

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Start date: November 8, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well an IRX-2 Regimen works in treating women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. The IRX-2 Regimen consists of a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole. IRX-2, a human cell-derived biologic with multiple active cytokine components, may act as an immune booster to stimulate the immune system. Giving cyclophosphamide and IRX-2 may work better at treating cervical squamous intraepithelial neoplasia or squamous vulvar intraepithelial neoplasia.

NCT ID: NCT03223753 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

Start date: November 29, 2017
Phase: Phase 3
Study type: Interventional

This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.

NCT ID: NCT03218436 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia

CAPCIN
Start date: August 31, 2017
Phase: N/A
Study type: Interventional

Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort. Primary endpoint after 3-6 months: Pathological remission. Secondary endpoint: HPV remission.

NCT ID: NCT03216421 Active, not recruiting - Breast Cancer Clinical Trials

Intraoperative Radiation Therapy (IORT) in DCIS

Start date: September 12, 2017
Phase: N/A
Study type: Interventional

The goal of this study is to examine the role of Intraoperative Radiotherapy (IORT) in Ductal Carcinoma In-Situ (DCIS) and to improve the understanding of the clinical, radiographic, and patient-related impact of adopting IORT.

NCT ID: NCT03196180 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Start date: September 30, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I clinical trial studies the side effects of topical fluorouracil and imiquimod ointment in treating patients with high-grade cervical intraepithelial neoplasia. Topical fluorouracil may kill precancerous cells. Imiquimod ointment may stimulate the immune system. Applying topical fluorouracil and imiquimod ointment may cause fewer side effects and may be a better way to treat patients with precancerous cervical lesions.

NCT ID: NCT03109522 Active, not recruiting - Clinical trials for Invasive Breast Cancer

Axillary Reverse Mapping (ARM) Technique

ARM
Start date: November 2016
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to compare a new surgical technique (axillary reverse mapping) to standard axillary surgery in patients diagnosed with invasive or in situ breast cancer.

NCT ID: NCT03084081 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

An Innovative Treatment for Cervical Precancer (UH3)

UH3
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this academic-industrial partnership will compare the CryoPen® and thermoablator to traditional CO2-based cryotherapy for the treatment of cervical precancer in low and middle income countries (LMICs) and investigate whether the cure rates of cervical intraepithelial neoplasia 2 and more severe diagnoses (CIN2+) with these devices are non-inferior compared to that of conventional cryotherapy. The results of this study will affect other research areas by serving as a springboard to exploring treatment alternatives that are amenable to low-resource settings and thus will reach the most vulnerable populations.